{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-055241","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.227502+00:00","generated_at":"2026-05-14T23:18:32.745694+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ocular Therapeutix Q1 net loss $88.6M; cash $666.7M; AXPAXLI NDA on track with SOL-1 data","bullets":["Net loss $88.6M ($0.40 per share) vs $64.1M ($0.38) in Q1 2025; revenue $10.8M, up 0.8%.","Cash $666.7M as of March 31, 2026; runway into 2028 excluding full AXPAXLI commercialization costs.","AXPAXLI NDA for wet AMD on track based on SOL-1 Week 52 data; subject to FDA discussions; 505(b)(2) pathway may shorten review.","SOL-1 positive: superior visual outcomes (74.1% maintained vision at Week 36 vs 55.8% aflibercept); p=0.0006 primary endpoint.","SOL-R non-inferiority trial on track for topline 1Q 2027; HELIOS-3 ongoing; Investor Day June 17, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-055241","json":"https://secwatch.observer/filing/0001104659-26-055241.json","markdown":"https://secwatch.observer/filing/0001104659-26-055241.md","text":"https://secwatch.observer/filing/0001104659-26-055241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/0001104659-26-055241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:18:32.745694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28fb8e3f0e95d976cc032abf8823ba9525bc00a0","claim":"OCULAR THERAPEUTIX, INC reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/0001104659-26-055241-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}